CCHT: Clinical trial application for GenSci143 injection has been accepted

LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the Zhitong Finance APP, Changchun Gaoxin (000661.SZ) announced that its subsidiary, Changchun JinSai Pharmaceutical Co., Ltd. ("JinSai Pharmaceutical"), received a written notice from the U.S. Food and Drug Administration ("FDA") that the clinical trial application for GenSci143 for injection has been accepted, with the indication being: advanced solid tumors

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.